Evidence map›Paper›PMID 41633435›Full record

ArticleVirologica Sinica2026

Genomic evidence of HMPV resurgence in Beijing: Clade B2 triggers the 2024 winter epidemic peak.

Lu Kang, Fang Huang, Yi-Mo Deng, Geng Hu, Yiting Wang, Aihua Li, Hui Xie, Xiaofeng Wei, Yuling Han, Ming Luo and 4 more

Abstract read
In one paragraph

Article in Virologica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Lu KangBeijing Key Laboratory of Surveillance, Early Warning and Pathogen Research on Emerging Infectious Diseases, Beijing Center for Disease Prevention and Control, Beijing 100013, China; School of Public Health, Capital Medical University, Beijing 100069, China; Beijing Research Center for Respiratory Infectious Diseases, Beijing 100013, China.
Fang HuangBeijing Key Laboratory of Surveillance, Early Warning and Pathogen Research on Emerging Infectious Diseases, Beijing Center for Disease Prevention and Control, Beijing 100013, China; School of Public Health, Capital Medical University, Beijing 100069, China; Beijing Research Center for Respiratory Infectious Diseases, Beijing 100013, China.
Yi-Mo DengWHO Collaborating Centre for Reference and Research on Influenza, VIDRL, Peter Doherty Institute for Infection and Immunity, Melbourne VIC 3000, Australia; School of Biomedical Sciences, The University of Western Australia, Perth, Western Australia, WA 6009, Australia.
Geng HuBeijing Key Laboratory of Surveillance, Early Warning and Pathogen Research on Emerging Infectious Diseases, Beijing Center for Disease Prevention and Control, Beijing 100013, China; School of Public Health, Capital Medical University, Beijing 100069, China; Beijing Research Center for Respiratory Infectious Diseases, Beijing 100013, China.
Yiting WangBeijing Key Laboratory of Surveillance, Early Warning and Pathogen Research on Emerging Infectious Diseases, Beijing Center for Disease Prevention and Control, Beijing 100013, China; School of Public Health, Capital Medical University, Beijing 100069, China; Beijing Research Center for Respiratory Infectious Diseases, Beijing 100013, China.
Aihua LiBeijing Key Laboratory of Surveillance, Early Warning and Pathogen Research on Emerging Infectious Diseases, Beijing Center for Disease Prevention and Control, Beijing 100013, China; School of Public Health, Capital Medical University, Beijing 100069, China; Beijing Research Center for Respiratory Infectious Diseases, Beijing 100013, China.
Hui XieBeijing Key Laboratory of Surveillance, Early Warning and Pathogen Research on Emerging Infectious Diseases, Beijing Center for Disease Prevention and Control, Beijing 100013, China; School of Public Health, Capital Medical University, Beijing 100069, China; Beijing Research Center for Respiratory Infectious Diseases, Beijing 100013, China.
Xiaofeng WeiBeijing Key Laboratory of Surveillance, Early Warning and Pathogen Research on Emerging Infectious Diseases, Beijing Center for Disease Prevention and Control, Beijing 100013, China; School of Public Health, Capital Medical University, Beijing 100069, China.
Yuling HanBeijing Key Laboratory of Surveillance, Early Warning and Pathogen Research on Emerging Infectious Diseases, Beijing Center for Disease Prevention and Control, Beijing 100013, China; School of Public Health, Capital Medical University, Beijing 100069, China.
Ming LuoBeijing Key Laboratory of Surveillance, Early Warning and Pathogen Research on Emerging Infectious Diseases, Beijing Center for Disease Prevention and Control, Beijing 100013, China; School of Public Health, Capital Medical University, Beijing 100069, China; Beijing Research Center for Respiratory Infectious Diseases, Beijing 100013, China.
Ian G BarrWHO Collaborating Centre for Reference and Research on Influenza, VIDRL, Peter Doherty Institute for Infection and Immunity, Melbourne VIC 3000, Australia; Department of Microbiology and Immunology, University of Melbourne, Melbourne, VIC 3000, Australia.
George F GaoCAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, CAS-TWAS Center of Excellence for Emerging Infectious Diseases (CEEID), Chinese Academy of Sciences, Beijing 100101, China. Electronic address: gaof@im.ac.cn.
Liang WangCAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, CAS-TWAS Center of Excellence for Emerging Infectious Diseases (CEEID), Chinese Academy of Sciences, Beijing 100101, China. Electronic address: wangliang@im.ac.cn.
Quanyi WangBeijing Key Laboratory of Surveillance, Early Warning and Pathogen Research on Emerging Infectious Diseases, Beijing Center for Disease Prevention and Control, Beijing 100013, China; School of Public Health, Capital Medical University, Beijing 100069, China; Beijing Research Center for Respiratory Infectious Diseases, Beijing 100013, China. Electronic address: wangqy@bjcdc.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With an unexpected increase of human metapneumovirus (hMPV) cases in northern China since late 2024, concerns arose whether novel hMPV variants triggered this epidemic. Utilizing the Beijing Respiratory Pathogen Surveillance System (RPSS), we conducted a genomic evolutionary analysis spanning 2014-2024 and revealed genetic information for the strains that caused the high rates of hMPV outbreaks during this period. To clarify the epidemic drivers and evolutionary characteristics of the hMPV strains circulating in Beijing, phylogenetic, population dynamic and mutation analyses were performed using high-quality complete sequences from both this study and publicly available data. A total of 348 high-quality hMPV genomes were obtained by next-generation sequencing (NGS), all of which belonged to four known clades: A2b1, A2b2, B1, and B2. Before 2024, A2b2 predominated in Beijing; however, a shift to clade B2 was observed starting in late 2024. In addition, a phylogenetically independent lineage Ⅰ was identified in this study, accounting for 93.1% of B2 genomes collected since late 2024. Furthermore, we identified several unique nonsynonymous mutations in viruses within lineage I that may have phenotypic implications. Our findings indicate that lineage I of clade B2 was the major cause of the unusual increase in hMPV outbreaks in Beijing in late 2024, with no evidence of an emerging novel variant. Although our data were only restricted to samples from Beijing, the findings are likely representative of the hMPV surge across northern China in 2024, given city's high population density and mobility.

Indexed as

Genome, ViralMetapneumovirusParamyxoviridae InfectionsBeijingEpidemicsEvolution, MolecularGenomicsHigh-Throughput Nucleotide SequencingHumansMutationPhylogenySeasonsAcute respiratory tract infections (ARTIs)GenomicsHuman metapneumovirus (hMPV)Next-generation sequencing (NGS)

Identifiers

PMID41633435
PMCPMC13007308

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.